> Detailanzeige

Paolisso, Pasquale; Bergamaschi, Luca; Gragnano, Felice; Gallinoro, Emanuele; Cesaro, Arturo; Sardu, Celestino; Mileva, Niya; Foà, Alberto; Armillotta, Matteo; Sansonetti, Angelo; Amicone, Sara; Impellizzeri, Andrea; Esposito, Giuseppe; Morici, Nuccia; Oreglia, Jacopo Andrea; Casella, Gianni; Mauro, Ciro; Vassilev, Dobrin; Galiè, Nazzareno; Marfella, Raffaele; Santulli, Gaetano; Calabrò, Paolo; Pizzi, Carmine; Barbato, Emanuele

528 OUTCOMES IN DIABETIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH SGLT2-I: THE SGLT2-I AMI PROTECT REGISTRY

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: 528 OUTCOMES IN DIABETIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH SGLT2-I: THE SGLT2-I AMI PROTECT REGISTRY
  • Beteiligte: Paolisso, Pasquale; Bergamaschi, Luca; Gragnano, Felice; Gallinoro, Emanuele; Cesaro, Arturo; Sardu, Celestino; Mileva, Niya; Foà, Alberto; Armillotta, Matteo; Sansonetti, Angelo; Amicone, Sara; Impellizzeri, Andrea; Esposito, Giuseppe; Morici, Nuccia; Oreglia, Jacopo Andrea; Casella, Gianni; Mauro, Ciro; Vassilev, Dobrin; Galiè, Nazzareno; Marfella, Raffaele; Santulli, Gaetano; Calabrò, Paolo; Pizzi, Carmine; Barbato, Emanuele
  • Erschienen: Oxford University Press (OUP), 2022
  • Erschienen in: European Heart Journal Supplements, 24 (2022) Supplement_K
  • Sprache: Englisch
  • DOI: 10.1093/eurheartjsupp/suac121.404
  • ISSN: 1554-2815; 1520-765X
  • Schlagwörter: Cardiology and Cardiovascular Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract Background Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) receive intense clinical interest in patients with and without type 2 diabetes mellitus (T2DM) for their pleiotropic beneficial effects. Objectives To investigate in-hospital and long-term prognosis in a cohort of T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic (OAD) agents (non-SGLT2-I users). Methods In this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention (PCI) between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. In-hospital outcomes included cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI). Long-term outcomes were cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization, and their composite (MACE). Results The study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p<0.05). During a median follow-up of 24±13 months, cardiovascular mortality, HF hospitalization and the composite endpoint were lower for SGLT2-I users compared to non-SGLT2-I patients (p<0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of HF hospitalization (HR=0.46; 95%CI:0.21-0.98; p=0.041) and MACE occurrence (HR=0.57; 95%CI:0.33-0.99; p=0.039). Conclusions In T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI.
  • Zugangsstatus: Freier Zugang